Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBERTY roll-over study of efanesoctocog alfa in haemophilia A
2023-506537-29-00Phase 3Authorised
- Sponsor
- Sobi
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, open-label, single-arm trial of N-acetyl cysteine + glutathione in hemophilia A, sponsored by Sobi. Primary endpoints: Safety - adverse events, Prophylaxis efficacy and 1 more. Planned start Apr 2024; status: authorised.
02
Drugs
N-acetyl cysteine + glutathione
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-506537-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506537-29-00.